SMTL ID : 5oq4.1

PQR309 - a Potent, Brain-Penetrant, Orally Bioavailable, pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.70 Å

Oligo State

monomer

Ligands

1 x A3W: 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine(Non-covalent)

A3W.1: 16 residues within 4Å: Chain A: M.662, S.664, I.689, K.691, D.694, L.696, D.699, E.738, I.739, V.740, T.745, K.748, M.811, F.819, I.821, D.822 4 PLIP interactions: 4 interactions with chain A Hydrogen bonds: A:D.699, A:V.740, A:K.748, A:D.822

2 x SO4: SULFATE ION(Non-functional Binders)

SO4.2: 6 residues within 4Å: Chain A: P.421, N.423, L.425, P.448, K.449, S.452 4 PLIP interactions: 4 interactions with chain A Hydrogen bonds: A:P.421, A:P.448, A:S.452 Salt bridges: A:K.449 SO4.3: 3 residues within 4Å: Chain A: E.507, K.541, R.545 2 PLIP interactions: 2 interactions with chain A Salt bridges: A:K.541, A:R.545

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Beaufils, F. et al., 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology. J. Med. Chem. (2017)

Release Date

2017-09-06

Peptides

Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform

Related Entries With Identical Sequence